EVANS AZAGIDI: Open Payments
NPI 1528530763 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,082 in 54 payments from 13 companies in 2025. Trend: 2023 $267 · 2024 $553 · 2025 $1,082
Food & beverage: $1,082
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 17 | $330 |
| Vanda Pharmaceuticals Inc. | 8 | $145 |
| Neurocrine BioSciences, Inc. | 4 | $102 |
| ABBVIE INC. | 5 | $97 |
| Janssen Pharmaceuticals, Inc | 3 | $88 |
| E.R. Squibb & Sons, L.L.C. | 3 | $59 |
| Alkermes, Inc. | 2 | $58 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $47 |
| Supernus Pharmaceuticals, Inc. | 3 | $44 |
| Lundbeck LLC | 2 | $42 |
Products named: REXULTI, FANAPT, INGREZZA, SPRAVATO, VRAYLAR, ABILIFY ASIMTUFII, COBENFY, ARISTADA.
Industry payments across NV — which companies pay providers there.
